Entering text into the input field will update the search result below

Galera Therapeutics readies IPO

Oct. 12, 2019 6:06 PM ETGalera Therapeutics, Inc. (GRTX)GRTXBy: Douglas W. House, SA News Editor
  • Galera Therapeutics (GRTX) has filed a preliminary prospectus for an $86M IPO.
  • The Malvern, PA-based biopharmaceutical firm develops therapeutics that, it says, have the potential to transform cancer radiotherapy by virtue of less tissue toxicity and greater efficacy. Specifically, its drugs mimic superoxide dismutase enzymes which protect against the toxicity of radiotherapy-stoked superoxide, a highly reactive molecule that damages/kills cells. Lead candidate is Phase 3-stage GC4419, a small molecule dismutase mimetic for the potential reduction of severe oral mucositis (OM) in patients with head and neck cancer (OM is a common side effect in these patients since they are routinely treated with radiation). Results from a mid-stage study showed a 92% reduction in median duration of OM compared to placebo.
  • 2019 Financials (6 mo.): Operating Expenses: $21.7M (+117%); Net Loss: ($21.9M) (-121%); Cash Burn: ($18.5M) (-71%).

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.